EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers

Alexandra M Gustafson, Aaron J Dinerman, Kyle J Hitscherich, Maria R Parkhurst, Hyunmi Halas, Donald E White, Chuong D Hoang, Jonathan M Hernandez, Mei Li M Kwong, Nicholas D Klemen, Steven A Rosenberg, Stephanie L Goff und 1 weitere

Cancer Immunology, Immunotherapy · 19.06.2025 · 74 (8)

DOI: 10.1007/s00262-025-04091-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.06.2025. Verfasst von Alexandra M Gustafson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Lymphocytes, Tumor-Infiltrating, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Cancer Research, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adoptive cell therapy with tumor infiltrating lymphocytes is FDA approved for metastatic melanoma. TIL from patients with melanoma and factors relating to growth and reactivity have been studied; however, this has not been explored in patients with epithelial cancers. Patients and methods Metastatic epithelial tumors resected for TIL growth from 2014 to 2023 were analyzed. Two hundred and ninety-one operations were performed to collect TIL for potential treatment. Of these, 263 harvests were each processed for up to 24 individual fragment cultures and screened for neoantigen recognition of the expressed products of cancer mutations. Patient and tumor characteristics were collected. Endpoints were growth (defined as more than half of all fragment cultures expanded for viable cryopreservation) and patient-specific neoantigen reactivity (release of interferon-γ in cocultures measured by ELISpot and 4-1BB upregulation on flow cytometry).

Results

TIL fragments reached adequate growth for screening by 21 days. Metastatic resections from lung were more likely to grow TIL than all other resection sites combined (95%, p = 0.0011), while hepatic resections were less likely to grow (69%, p < 0.0001). One hundred and thirty-five patients (51%) had highly reactive TIL, 68 (26%) had weakly reactive TIL, and 60 (23%) had TIL with no neoantigen reactivity. Patients with prior exposure to immune checkpoint blockade therapy were less likely to have highly reactive TIL ( p = 0.0325). Metastatic resection site impacted TIL reactivity against neoantigens, with those harvested from the lung more likely to show any reactivity (83%, p = 0.0180), as well as high reactivity (59%, p = 0.0066).

Conclusions

Prior immune checkpoint therapies reduced the likelihood of having highly reactive TIL. Neoantigen reactivity was more common in TIL from thoracic resections versus other sites. Conversely, hepatic lesions yielded TIL less likely to grow and with less reactivity. These results contribute to improved strategies for sequencing TIL with other therapies and planning TIL harvests for patients with epithelial cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmLymphocytes, Tumor-InfiltratingNeoplasms, Glandular and EpithelialHumansFemaleMaleMiddle AgedAgedAdultNeoplasm MetastasisImmunotherapy, AdoptiveAged, 80 and over

Stichwörter der Autor:innen

Adoptive cell transferMetastatic solid tumorsTumor infiltrating lymphocytes

Substanzen

Antigens, Neoplasm

Autor:innen und Institutionen

  • Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jamesyang@mail.nih.gov.

Förderung

  • Center for Cancer Research
  • National Cancer Institute

Zitieren

APA

Gustafson, A. M., Dinerman, A. J., Hitscherich, K. J., Parkhurst, M. R., Halas, H., White, D. E., Hoang, C. D., Hernandez, J. M., Kwong, M. L. M., Klemen, N. D., Rosenberg, S. A., Goff, S. L., & Yang, J. C. (2025). Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers. Cancer Immunology, Immunotherapy, 74(8). https://doi.org/10.1007/s00262-025-04091-3

Vancouver

Gustafson AM, Dinerman AJ, Hitscherich KJ, Parkhurst MR, Halas H, White DE, et al. Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers. Cancer Immunology, Immunotherapy. 2025;74(8). doi:10.1007/s00262-025-04091-3

BibTeX
@article{Gustafson2025,
  author = {Gustafson, Alexandra M and Dinerman, Aaron J and Hitscherich, Kyle J and Parkhurst, Maria R and Halas, Hyunmi and White, Donald E and Hoang, Chuong D and Hernandez, Jonathan M and Kwong, Mei Li M and Klemen, Nicholas D and Rosenberg, Steven A and Goff, Stephanie L and Yang, James C},
  title = {Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {8},
  doi = {10.1007/s00262-025-04091-3}
}
Kostenlos starten →